Jazz Pharmaceuticals to Present at Investor C...( PALO ALTO Calif. Nov. 4 /- JazzPh...),Health
Navigation Links
Jazz Pharmaceuticals to Present at Investor Conferences
Date:11/4/2008
PALO ALTO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the company will present at three upcoming investor conferences.
On Tuesday, November 11, 2008 at 2:50 p.m. EST, Dr. Samuel R. Saks, Jazz Pharmaceuticals' CEO, will provide a corporate presentation at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City.
On Wednesday, November 12, 2008 at 3:30 p.m. MST (5:30 p.m. EST), Dr. Saks will provide a corporate presentation at the Credit Suisse Healthcare Conference in Phoenix.
On Wednesday, November 19, 2008 at 11:30 a.m. EST, Robert M. Myers, President of Jazz Pharmaceuticals, will provide a corporate presentation at the Lazard Capital Markets 5th Annual Healthcare Conference in New York City.
A live webcast of these presentations may be accessed by visiting the Investors section of the Jazz Pharmaceuticals website at http://www.JazzPharmaceuticals.com. A replay will be available on the site for two weeks following each presentation.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
'/>"/>
| SOURCE Jazz Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
3. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
4. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
5. Genesis Pharmaceuticals Files Counter Claims
6. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
10. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
11. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
Post Your Comments:
Breaking Medicine News(10 mins):Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Help Young Cancer Patients Enjoy Christmas This Season 2
[0] New Blood Thinner Could Replace Warfarin to Fight Venous Clots[0] New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V)[0] Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists[0] Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference[0] Help Young Cancer Patients Enjoy Christmas This Season
Other Medicine News:Health News:WellPoint Announces Strategic Relationship With Availity to Enhance the Provider and Health Plan Relationship and Advance Improvements in Patient Care 2Health News:WellPoint Announces Strategic Relationship With Availity to Enhance the Provider and Health Plan Relationship and Advance Improvements in Patient Care 3Health News:Hologic to Release Second Quarter Fiscal 2009 Operating Results on Monday, May 4, 2009 2Health News:New strategy to weaken traumatic memories 2Health News:CUREXO Technology Corporation Receives Quality Certificate 2Health News:Lice Safe Introduces Licen Tool 2
WellPoint Announces Strategic Relationship With Availity to Enhance the Provider and Health Plan Relationship and Advance Improvements in Patient CareHologic to Release Second Quarter Fiscal 2009 Operating Results on Monday, May 4, 2009New strategy to weaken traumatic memoriesCUREXO Technology Corporation Receives Quality CertificateLice Safe Introduces Licen ToolBlack Male Children Face Highest Risk for Food Allergies
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Obese Middle Aged Women Face Unhealthy Future 58481 1Obese Middle Aged Women Face Unhealthy Future 58481 2Combining sun sand and science in the Bahamas 10172 1Combining sun sand and science in the Bahamas 10172 2Combining sun sand and science in the Bahamas 10172 3Mystery solved 3A Marine microbe is source of rare nutrient 10169 1Mystery solved 3A Marine microbe is source of rare nutrient 10169 2Mystery solved 3A Marine microbe is source of rare nutrient 10169 3
Other Medicine Technology:ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |